Three Year Analysis Of Treatment Efficacy, Cosmesis, And Toxicity Support Use Of The Hologic Mammosite Radiation Therapy System

Hologic, Inc. (Nasdaq: HOLX) a diversified medical technologies company specializing in imaging systems, diagnostics, and interventional devices dedicated to serving the healthcare needs of women, announced the publication of a study evaluating the Hologic MammoSite(R) Radiation Therapy System (RTS), one-, two- and three-years after treatment. The study by Frank A. Vicini, M.D.

More: continued here

Filed under: Breast Cancer on February 26th, 2008